High expectation on ‘Lynparza,’ BRCA-mutated ovarian cancer targeted treatment
‘Lynparza,’ a targeted therapy for ovarian cancer known for its low survival rate and high recurrence rate, was launched in Korea.
On the 26th, AstraZeneca Korea(hereinafter referring to AZ) announced the launch of ‘Lynparza(generic name: olaparib),’ the first ovarian cancer targeted therapy usi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
